Cohance Lifesciences Limited — Others, 13-02-2025: Copy of Newspaper Publication

Suven Pharmaceuticals has announced a board meeting to discuss the financial results for the quarter and nine months ended December 31, 2024. The total income from operations for the quarter was ₹1,945.36 crore with a net profit of ₹30.76 crore. For the nine months, total income reached ₹6,919.93 crore, and net profit stood at ₹1,782.62 crore. This performance indicates strong operational resilience, reflecting potential growth opportunities in the biopharmaceutical sector, despite a moderate dip in quarterly profits compared to previous periods. Investors may view this as a neutral impact, focusing on long-term growth possibilities.